Ask any UK telehealth operator where their service draws the line on age, and the honest answer is rarely "wherever the law allows". Most set their own floor well above it, commonly 16 or sometimes 18, regardless of whether an individual teenager could pass a competence test to consent. That gap between what the law permits and what a remote-only model can safely deliver is where most of the real paediatric risk in telehealth actually sits.
Why most services set the floor above the legal minimum
Ask a UK telehealth operator where their service draws the age line and the honest answer is rarely "wherever the law allows". Gillick competence is a consent test: it asks whether a young person understands enough about a specific treatment to agree to it themselves. It says nothing about whether a remote service can safely weigh, dose, or dispense to them.
Most operators set their own floor well above that consent test, commonly 16 or 18, as a deliberate business and clinical-governance decision rather than a legal minimum. That gap between what the law permits and what a remote-only model can safely deliver is where most of the real paediatric risk in telehealth sits, and it is worth designing for on purpose rather than discovering it by incident.
The classification rules that already restrict some products by age
Some of the age restriction is already built into how medicines are classified, before a telehealth operator makes any policy choice of its own. A handful of examples show the pattern:
- Aspirin-containing products are not recommended for children and young people under 16, except on specific medical advice, because of the established Reye's syndrome caution.
- Several General Sale List and Pharmacy medicines carry manufacturer age warnings that a pharmacist is expected to apply at the point of supply, not just print on a label.
- Prescription-only medicines with a paediatric indication are usually licensed for named age or weight bands, and dosing outside those bands sits outside the product licence.
- Distance-selling requirements and a pharmacy's own standard operating procedures typically assume an adult purchaser, so paediatric supply often needs a separate SOP rather than a footnote on the adult one.
None of this is exotic. It is the normal texture of pharmacy regulation, which is exactly why "we'll just add an under-16 pathway" is rarely the small feature it sounds like.
Why remote dosing, not consent, is the harder problem
Consent is the part most operators think about first, and it is also the easiest to solve: ask the right questions, document capacity, involve a parent where appropriate. Dosing is harder, because it depends on something a screen cannot reliably capture: an accurate, current weight.
Children's doses are usually calculated per kilogram and reviewed at intervals as they grow, and a remote consultation has no equivalent of the community pharmacist's counter conversation or a GP practice's recent weighing record. Work from a figure a family estimated rather than measured, and the safety margin most paediatric dosing relies on narrows fast.
The age floor a UK telehealth service sets should sit above the Gillick competence test, not at it: consent tells you whether a young person can agree to treatment, not whether a remote-only model can weigh, dose, and package for them safely.
Packaging and dispensing cautions when a household includes children
Age risk does not stop once a prescription is issued. It travels with the parcel, particularly for adult patients who happen to share a house with children.
- Child-resistant closures are expected on many oral liquid and higher-strength solid-dose preparations, and under GPhC dispensing standards a pharmacy is expected to apply them as a matter of course, not on request.
- Same-day courier packaging should avoid printing the medicine name prominently on the outer parcel, reducing the chance a child associates a familiar box with something safe to open.
- Dispatch notes and patient information leaflets should carry plain "keep out of reach of children" guidance even when the patient themselves is an adult.
- Look-alike risk between a patient's own medicines and household products is worth flagging in onboarding materials, especially for repeat-dispensing patients building up a supply at home.
None of this needs to be dramatic. It needs to be routine, written down, and checked, the same way any other dispensing safety control is.
Where telehealth can safely serve under-18s, and where it can't
There are narrow, well-defined places where UK telehealth already serves under-18s safely: certain sexual health services extend to 16- and 17-year-olds with clear safeguarding protocols built in, and some allergy or minor-ailment pathways will see a 16-year-old with parental involvement designed into the consultation.
Outside those specific, well-scoped pathways, the safer default is referral rather than a stretched eligibility gate: a GP, a community pharmacy, or a paediatric-specific service that can weigh, examine, and follow up in person. Building that referral relationship in advance costs far less than discovering the gap mid-consultation.
Gillick competence tells you whether a teenager can consent. It doesn't tell you whether your service can weigh them, dose them safely, or check who else lives in the house.
Build the referral pathway, don't stretch the eligibility gate
The practical fix is not a longer terms-and-conditions clause. It is an intake flow that asks age early, states the floor plainly, and offers a next step rather than a dead end, tied to the operator's own identity verification and age-verification controls so the gate is enforced consistently rather than left to a tick-box.
Safety-netting language matters here too. "We don't treat under-16s for this condition, please see your GP or call NHS 111" reads very differently to a worried parent than a bare rejection message, and it closes the loop instead of leaving a family to work out the next step alone. This belongs in the same clinical SOP that covers every other safety-netting scenario.
Where PExpo fits
This is one of the quieter reasons operators use a shared dispensing layer rather than building age controls fresh for every brand. PExpo's intake and dispensing workflow lets an operator configure its own age floor once, above the statutory minimum where the clinical model requires it, and apply it consistently across identity checks, prescribing, and packaging instructions rather than relying on a single form field to catch every case.
None of this replaces clinical judgement. A superintendent pharmacist still sets the policy and a prescriber still makes the individual decision; the platform's job is to make sure that decision is applied the same way for the tenth patient as the first, with the packaging and referral steps built in rather than bolted on afterwards.
Paediatric risk in UK telehealth rarely announces itself as a legal problem. It shows up as a dosing question nobody can answer remotely, a parcel that arrives in a house with young children, or a family that gets a rejection message with nowhere to turn next. Setting the age floor deliberately, above the consent test, and backing it with a real referral pathway and the packaging discipline covered in our tamper-evidence guide, turns a gap into a controlled boundary instead of an incident waiting to happen.
Frequently asked questions
What age should a UK telehealth service set as its minimum?
There's no single statutory age that applies to every service; it depends on the condition, the medicines involved, and the clinical model. Many operators set 16 or 18 as a deliberate policy floor, above the Gillick competence test, because remote consultations struggle to replicate the weighing, examination, and packaging checks a face-to-face paediatric service can offer.
Is Gillick competence the same thing as an age policy?
No. Gillick competence is a legal test of whether a young person understands enough about a specific treatment to consent to it themselves. It doesn't determine whether a telehealth operator's model can safely deliver that treatment remotely, which is a separate clinical and operational decision the operator has to make.
What should happen when a service turns away an under-age patient?
A clear, documented referral, not a bare rejection. Good practice points the patient or parent to their GP, a community pharmacy, or NHS 111, and records the interaction as part of the operator's safety-netting process rather than treating it as a dead end.
